thebench.bio #1 Ecosystem for the Bio-Tech Industry

Life Sciences Daily Summary

Life Sciences Daily Summary: What Happened on November 15, 2026

FDA rejects Summit and Akeso’s ivonescimab for lung cancer

The decision turns on a gap between delaying disease progression and extending patients’ lives.

  • Updated
  • Read from 1 article, 1 publication

Today in brief

Summit said the FDA refused to approve ivonescimab, its lung cancer treatment developed with Akeso.1 Reviewers said the drug’s effect on cancer progression did not offset its failure to extend patients’ lives in the FDA’s benefit-risk assessment.1

FDA says ivonescimab did not show a survival benefit

Summit Therapeutics said the FDA rejected ivonescimab, which it developed with Akeso for a type of lung cancer.1 In its letter to the companies, the FDA said the drug could not be approved because it had not extended patients’ lives.1

The treatment slowed the worsening of patients’ cancer, but FDA reviewers said that result did not establish a favorable benefit-risk profile without a survival benefit.1